Literature DB >> 21827905

Machado-Joseph disease/spinocerebellar ataxia type 3.

Henry Paulson1.   

Abstract

Machado-Joseph disease (MJD), also known as spinocerebellar ataxia type 3 (SCA3), may be the most common dominantly inherited ataxia in the world. Here I will review historical, clinical, neuropathological, genetic, and pathogenic features of MJD, and finish with a brief discussion of present, and possible future, treatment for this currently incurable disorder. Like many other dominantly inherited ataxias, MJD/SCA3 shows remarkable clinical heterogeneity, reflecting the underlying genetic defect: an unstable CAG trinucleotide repeat that varies in size among affected persons. This pathogenic repeat in MJD/SCA3 encodes an expanded tract of the amino acid glutamine in the disease protein, which is known as ataxin-3. MJD/SCA3 is one of nine identified polyglutamine neurodegenerative diseases which share features of pathogenesis centered on protein misfolding and accumulation. The specific properties of MJD/SCA3 and its disease protein are discussed in light of what is known about the entire class of polyglutamine diseases. 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21827905      PMCID: PMC3568768          DOI: 10.1016/B978-0-444-51892-7.00027-9

Source DB:  PubMed          Journal:  Handb Clin Neurol        ISSN: 0072-9752


  137 in total

1.  Relationship of (CAG)nC configuration to repeat instability of the Machado-Joseph disease gene.

Authors:  R Matsumura; T Takayanagi; K Murata; N Futamura; M Hirano; S Ueno
Journal:  Hum Genet       Date:  1996-12       Impact factor: 4.132

2.  Machado-Joseph disease in four Chinese pedigrees: molecular analysis of 15 patients including two juvenile cases and clinical correlations.

Authors:  Y X Zhou; Y Takiyama; S Igarashi; Y F Li; B Y Zhou; D C Gui; K Endo; H Tanaka; Z H Chen; L S Zhou; M Z Fan; B X Yang; J Weissenbach; G X Wang; S Tsuji
Journal:  Neurology       Date:  1997-02       Impact factor: 9.910

3.  Mosaicism of the CAG repeat in CNS tissue in relation to age at death in spinocerebellar ataxia type 1 and Machado-Joseph disease patients.

Authors:  P Maciel; I Lopes-Cendes; S Kish; J Sequeiros; G A Rouleau
Journal:  Am J Hum Genet       Date:  1997-04       Impact factor: 11.025

4.  The natural history of degenerative ataxia: a retrospective study in 466 patients.

Authors:  T Klockgether; R Lüdtke; B Kramer; M Abele; K Bürk; L Schöls; O Riess; F Laccone; S Boesch; I Lopes-Cendes; A Brice; R Inzelberg; N Zilber; J Dichgans
Journal:  Brain       Date:  1998-04       Impact factor: 13.501

5.  Intrafamilial variability in Machado-Joseph disease.

Authors:  S H Subramony; R D Currier
Journal:  Mov Disord       Date:  1996-11       Impact factor: 10.338

6.  Machado-Joseph disease: clinical, molecular, and metabolic characterization in Chinese kindreds.

Authors:  B Soong; C Cheng; R Liu; D Shan
Journal:  Ann Neurol       Date:  1997-04       Impact factor: 10.422

7.  Machado-Joseph disease gene product is a cytoplasmic protein widely expressed in brain.

Authors:  H L Paulson; S S Das; P B Crino; M K Perez; S C Patel; D Gotsdiner; K H Fischbeck; R N Pittman
Journal:  Ann Neurol       Date:  1997-04       Impact factor: 10.422

8.  Regional and cellular expression of the Machado-Joseph disease gene in brains of normal and affected individuals.

Authors:  K Nishiyama; S Murayama; J Goto; M Watanabe; H Hashida; S Katayama; Y Nomura; S Nakamura; I Kanazawa
Journal:  Ann Neurol       Date:  1996-11       Impact factor: 10.422

9.  Relations between genotype and phenotype in German patients with the Machado-Joseph disease mutation.

Authors:  L Schöls; G Amoiridis; J T Epplen; M Langkafel; H Przuntek; O Riess
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-11       Impact factor: 10.154

10.  Poly-ubiquitin binding by the polyglutamine disease protein ataxin-3 links its normal function to protein surveillance pathways.

Authors:  Yaohui Chai; Sarah Shoesmith Berke; Robert E Cohen; Henry L Paulson
Journal:  J Biol Chem       Date:  2003-11-05       Impact factor: 5.157

View more
  58 in total

1.  Clinical Reasoning: A 72-year-old man with nocturnal stridor.

Authors:  José Rafael P Zuzuárregui; Anand Shah; Marie-Helene Saint-Hilaire
Journal:  Neurology       Date:  2015-11-03       Impact factor: 9.910

Review 2.  The role for alterations in neuronal activity in the pathogenesis of polyglutamine repeat disorders.

Authors:  Ravi Chopra; Vikram G Shakkottai
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

3.  miR-25 alleviates polyQ-mediated cytotoxicity by silencing ATXN3.

Authors:  Fengzhen Huang; Li Zhang; Zhe Long; Zhao Chen; Xuan Hou; Chunrong Wang; Huirong Peng; Junling Wang; Jiada Li; Ranhui Duan; Kun Xia; De-Maw Chuang; Beisha Tang; Hong Jiang
Journal:  FEBS Lett       Date:  2014-11-20       Impact factor: 4.124

4.  Promoter Variant Alters Expression of the Autophagic BECN1 Gene: Implications for Clinical Manifestations of Machado-Joseph Disease.

Authors:  Nadiya Kazachkova; Mafalda Raposo; Amanda Ramos; Rafael Montiel; Manuela Lima
Journal:  Cerebellum       Date:  2017-12       Impact factor: 3.847

5.  Non-Ataxic Presenting Symptoms of Dominant Ataxias.

Authors:  Elsdon Storey
Journal:  Cerebellum       Date:  2016-02       Impact factor: 3.847

Review 6.  The autosomal dominant spinocerebellar ataxias: emerging mechanistic themes suggest pervasive Purkinje cell vulnerability.

Authors:  Katherine E Hekman; Christopher M Gomez
Journal:  J Neurol Neurosurg Psychiatry       Date:  2014-08-18       Impact factor: 10.154

Review 7.  The impact of histone post-translational modifications in neurodegenerative diseases.

Authors:  Samantha N Cobos; Seth A Bennett; Mariana P Torrente
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-10-20       Impact factor: 5.187

Review 8.  Polyglutamine spinocerebellar ataxias - from genes to potential treatments.

Authors:  Henry L Paulson; Vikram G Shakkottai; H Brent Clark; Harry T Orr
Journal:  Nat Rev Neurosci       Date:  2017-08-17       Impact factor: 34.870

Review 9.  The neurogenetics of atypical parkinsonian disorders.

Authors:  Brent L Fogel; Mary C Clark; Daniel H Geschwind
Journal:  Semin Neurol       Date:  2014-06-25       Impact factor: 3.420

10.  Lithium chloride alleviates neurodegeneration partly by inhibiting activity of GSK3β in a SCA3 Drosophila model.

Authors:  Dan-Dan Jia; Li Zhang; Zhao Chen; Chun-Rong Wang; Feng-Zhen Huang; Ran-Hui Duan; Kun Xia; Bei-Sha Tang; Hong Jiang
Journal:  Cerebellum       Date:  2013-12       Impact factor: 3.847

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.